PATENT CLAIM ANALYSIS

Application Number: 16184748
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["435", "006100"]

Abstract:
A gene expression signature identifies stage II colon and/or Stage III cancer patients who will receive benefit from oxaliplatin. Oxaliplatin has been shown to lengthen the survival of colon cancer patients, when it is combined with 5-fluorouracil plus leucovorin (FULV) in NSABP clinical trial C-07. Gene expression signatures are used first to classify tumors with regard to their respective subtypes, enterocyte, TA, goblet, inflammatory and stem-like and detection of expression of the enterocyte subtype directs treatment of the patient with oxaliplatin.

Claim (Index 4):
The method of  claim 2 , wherein the identified tumor tissue subtype is of the enterocyte tissue type.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 98.0
- Lexical Diversity: 1.33824
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14738757', '14346693', '14209266', '13992020', '13401780']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5500462415557704
- 35 USC 102 Novelty (BERT): 0.6179176563373071
- Combined Prediction Score: 0.556833383033924
- Mean Citation Score: 303.936754
- Max Citation Score: 671.14923
- Similarity Product: 462.7001316354615

Labels:
- Claim Label 101: 0
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test